Targets, Modulators and Delivery Program
靶标、调节剂和交付计划
基本信息
- 批准号:10270904
- 负责人:
- 金额:$ 9.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-09-05 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:Acute leukemiaAdultAntineoplastic AgentsAwardBasic ScienceCancer BiologyCancer CenterCancer Center Support GrantChemicalsChildhoodClinicClinical TrialsCollaborationsComputer AnalysisCustomDetectionDevelopmentDirect CostsDockingEvaluationFacultyFoundationsFundingFutureGene ExpressionGeneticGoalsHematologistHyaluronic AcidIntellectual PropertyInvestigationInvestmentsJournalsLymphomaMalignant NeoplasmsMalignant neoplasm of gastrointestinal tractMalignant neoplasm of lungMalignant neoplasm of ovaryMalignant neoplasm of pancreasMethodsMissionMolecularMolecular TargetMultiple MyelomaNCI Center for Cancer ResearchNano deliveryNebraskaOncogenesOncologistOncologyPediatric HematologistPeer ReviewPharmaceutical ChemistryPharmacologyPhysiciansPopulationProtacPublicationsRNA InterferenceRadiation OncologistRegulationReportingResearchResearch PersonnelResource SharingResourcesScientistSignal TransductionStructureSurgical OncologistSynthesis ChemistryTechnologyTechnology TransferTestingTherapeuticTraining and EducationTranslational ResearchTranslationsValidationbasebench to bedsidecancer cellcancer imagingcancer therapyclinical translationcommercializationcomputational chemistrycopolymerdrug developmentin silicointer-institutionalinterestmalignant breast neoplasmmedulloblastomamembernanomaterialsneoplastic cellnew technologynext generationnovelnovel strategiespreclinical studyprogramsprospectivesmall moleculetooltranslational research programtranslational studytumor
项目摘要
Project Summary/Abstract: Targets, Modulators, and Delivery Program (TMDP)
The mission of the Targets, Modulators, and Delivery Program (TMDP; formerly known as the Cancer Genes
and Molecular Regulation Program) is to validate targets, develop small molecules that modulate cancer targets,
and develop methods for efficient delivery of modulators to tumor cells. The TMDP is organized to promote
collaboration and catalyze the translation of scientific discoveries from Fred & Pamela Buffett Cancer Center
(BCC) basic research program members while providing BCC translational research programs access to
validated targets, small molecule modulators, and delivery methods for clinical translation. The TMDP integrates
the efforts of 18 physician-scientists (including adult and pediatric hematologist/oncologists, radiation oncologists
and surgical oncologists) with expertise in clinical trial development and 23 investigators with expertise in cancer
target development, medicinal chemistry, pharmacology, and nanodelivery. Together, the program members
develop tools and technology to facilitate translation of basic science discoveries by the bench-to-bedside
continuum within BCC research programs. Resources developed by the TMDP to support novel chemical entity
(NCE) discovery/development within the TMDP and the BCC include the Synthetic and Medicinal Chemistry
Resource, PROteolysis Targeting Chimera (PROTAC) synthesis and Computational Chemistry Resource. The
translational research efforts of the TMDP faculty extend across the full range of malignancies that are of critical
importance to the population of Nebraska, including lung cancer, ovarian cancer, multiple myeloma, lymphoma,
acute leukemia, breast cancer, pancreatic cancer and medulloblastoma. The research interests of TMDP faculty
are organized around three interactive themes – Target Validation, Small Molecule Modulators, Delivery Methods
– that contribute to the overarching goal of bench-to-bedside research translation through intra- and inter-
programmatic collaboration. These themes exemplify the specific aims of the TMDP to 1) develop conceptual
and technical approaches to validate cancer targets; 2) identify and characterize target- and mechanism-specific
small molecules directed at validated cancer targets; and 3) explore novel technologies for efficient delivery of
small molecules or RNAi against validated cancer targets. Physician scientists within the TMDP with clinical
trials expertise facilitate the translation of putative targets, chemical modulators, and delivery methods with
therapeutic potential. The interactions between TMDP members, their interactions with other BCC Programs,
and their inter-institutional collaborations promote impactful and translational studies. These interactions have
resulted in $4.25M (direct) of cancer-relevant peer-reviewed funding to TMDP investigators, with 3.17M from the
NCI. During the funding period, the TMDP investigators reported 647 cancer-relevant publications (average
journal impact factor = 7), with 37% intra-programmatic, 28% inter-programmatic, 18% both intra- and inter-
programmatic and 41% inter-institutional publications.
项目摘要/摘要:目标、调制器和交付计划(TMDP)
靶标、调节剂和传递计划(TMDP;以前称为癌症基因)的使命
和分子调控计划)是验证靶点,开发调节癌症靶点的小分子,
并开发有效地将调节剂输送到肿瘤细胞的方法。TMDP的组织是为了促进
合作并催化将弗雷德和帕梅拉·巴菲特癌症中心的科学发现转化为
(BCC)基础研究计划成员,同时为BCC翻译研究计划提供访问权限
临床翻译的有效靶点、小分子调节剂和递送方法。TMDP集成了
18名内科科学家(包括成人和儿童血液学家/肿瘤学家、放射肿瘤学家)的努力
和外科肿瘤学家),具有临床试验开发专业知识和23名具有癌症专业知识的研究人员
目标开发、药物化学、药理学和纳米递送。总之,项目成员
开发工具和技术,以促进基础科学发现的现场转化
BCC研究计划中的连续体。TMDP为支持新的化学实体而开发的资源
(NCE)TMDP和BCC内的发现/开发包括合成和药物化学
资源,针对嵌合体的蛋白质分解(PROTAC)合成和计算化学资源。这个
TMDP教员的转译研究工作涵盖了所有危急的恶性肿瘤
对内布拉斯加州人口的重要性,包括肺癌,卵巢癌,多发性骨髓瘤,淋巴瘤,
急性白血病、乳腺癌、胰腺癌和髓母细胞瘤。TMDP教职员工的研究兴趣
围绕三个互动主题组织-靶标验证、小分子调节剂、传递方法
-有助于通过内部和外部研究实现从工作台到床边的研究翻译的总体目标
程序性协作。这些主题体现了TMDP的具体目标,即1)发展概念性
以及验证癌症靶点的技术方法;2)识别和表征特定靶点和机制
针对有效的癌症靶点的小分子;以及3)探索有效传递
针对有效的癌症靶点的小分子或RNAi。TMDP内的内科科学家与临床
试验专业知识有助于翻译假定的靶标、化学调节剂和给药方法
治疗潜力。TMDP成员之间的互动,他们与其他BCC程序的互动,
他们的机构间合作促进了有影响力的研究和翻译研究。这些相互作用具有
为TMDP调查人员提供了425万美元(直接)的癌症相关同行审查资金,其中317万来自
美国国家情报局。在资助期间,TMDP调查人员报告了647篇与癌症有关的出版物(平均
期刊影响系数=7),方案内占37%,方案间占28%,方案内和方案间均占18%
方案出版物和41%的机构间出版物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sarah A Holstein其他文献
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
基于达雷妥尤单抗的四联疗法治疗符合移植资格的新诊断的具有高细胞遗传学风险的多发性骨髓瘤
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:12.8
- 作者:
Natalie S. Callander;R. Silbermann;Jonathan L. Kaufman;K. Godby;J. Laubach;T. Schmidt;Douglas W Sborov;E. Medvedova;B. Reeves;B. Dhakal;Cesar Rodriguez;S. Chhabra;A. Chari;S. Bal;Larry D. Anderson;B. Dholaria;N. Nathwani;P. Hari;Nina Shah;N. Bumma;Sarah A Holstein;Caitlin Costello;A. Jakubowiak;T. M. Wildes;R. Orlowski;K. Shain;Andrew J Cowan;H. Pei;A. Cortoos;Sharmila Patel;Thomas S. Lin;Smith Giri;Luciano J Costa;Saad Z Usmani;Paul G Richardson;P. Voorhees - 通讯作者:
P. Voorhees
Sarah A Holstein的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sarah A Holstein', 18)}}的其他基金
Geranylgeranyl diphosphate synthase inhibitor therapy for multiple myeloma
香叶基香叶基二磷酸合酶抑制剂治疗多发性骨髓瘤
- 批准号:
10364685 - 财政年份:2021
- 资助金额:
$ 9.49万 - 项目类别:
Geranylgeranyl diphosphate synthase inhibitor therapy for multiple myeloma
香叶基香叶基二磷酸合酶抑制剂治疗多发性骨髓瘤
- 批准号:
10600005 - 财政年份:2021
- 资助金额:
$ 9.49万 - 项目类别:
Geranylgeranyl diphosphate synthase inhibitor therapy for multiple myeloma
香叶基香叶基二磷酸合酶抑制剂治疗多发性骨髓瘤
- 批准号:
10180333 - 财政年份:2021
- 资助金额:
$ 9.49万 - 项目类别:
Rab Geranylgeranylation: a Novel Therapeutic Target in Multiple Myeloma
Rab 香叶基香叶基化:多发性骨髓瘤的新治疗靶点
- 批准号:
9331012 - 财政年份:2013
- 资助金额:
$ 9.49万 - 项目类别:
Rab Geranylgeranylation: a Novel Therapeutic Target in Multiple Myeloma
Rab 香叶基香叶基化:多发性骨髓瘤的新治疗靶点
- 批准号:
8988538 - 财政年份:2013
- 资助金额:
$ 9.49万 - 项目类别:
Rab Geranylgeranylation: a Novel Therapeutic Target in Multiple Myeloma
Rab 香叶基香叶基化:多发性骨髓瘤的新治疗靶点
- 批准号:
8416249 - 财政年份:2013
- 资助金额:
$ 9.49万 - 项目类别:
Rab Geranylgeranylation: a Novel Therapeutic Target in Multiple Myeloma
Rab 香叶基香叶基化:多发性骨髓瘤的新治疗靶点
- 批准号:
8600246 - 财政年份:2013
- 资助金额:
$ 9.49万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 9.49万 - 项目类别:
Research Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 9.49万 - 项目类别:
Standard Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 9.49万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 9.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 9.49万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 9.49万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 9.49万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 9.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 9.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 9.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)